Browse CCL15

Summary
SymbolCCL15
Namechemokine (C-C motif) ligand 15
Aliases NCC-3; MIP-5; Lkn-1; MIP-1d; HMRP-2B; leukotactin 1; CC chemokine 3; macrophage inflammatory protein 5; chem ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00048 Small cytokines (intecrine/chemokine)
Function

Chemotactic factor that attracts T-cells and monocytes, but not neutrophils, eosinophils, or B-cells. Acts mainly via CC chemokine receptor CCR1. Also binds to CCR3. CCL15(22-92), CCL15(25-92) and CCL15(29-92) are more potent chemoattractants than the small-inducible cytokine A15.

> Gene Ontology
 
Biological Process GO:0002548 monocyte chemotaxis
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0030593 neutrophil chemotaxis
GO:0030595 leukocyte chemotaxis
GO:0031349 positive regulation of defense response
GO:0032103 positive regulation of response to external stimulus
GO:0034341 response to interferon-gamma
GO:0034612 response to tumor necrosis factor
GO:0043410 positive regulation of MAPK cascade
GO:0048247 lymphocyte chemotaxis
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0050900 leukocyte migration
GO:0050918 positive chemotaxis
GO:0055074 calcium ion homeostasis
GO:0060326 cell chemotaxis
GO:0070098 chemokine-mediated signaling pathway
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070555 response to interleukin-1
GO:0071346 cellular response to interferon-gamma
GO:0071347 cellular response to interleukin-1
GO:0071356 cellular response to tumor necrosis factor
GO:0071621 granulocyte chemotaxis
GO:0071674 mononuclear cell migration
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072676 lymphocyte migration
GO:0097529 myeloid leukocyte migration
GO:0097530 granulocyte migration
GO:1990266 neutrophil migration
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005539 glycosaminoglycan binding
GO:0008009 chemokine activity
GO:0008201 heparin binding
GO:0042056 chemoattractant activity
GO:0042379 chemokine receptor binding
GO:0048020 CCR chemokine receptor binding
GO:1901681 sulfur compound binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway
Reactome -
Summary
SymbolCCL15
Namechemokine (C-C motif) ligand 15
Aliases NCC-3; MIP-5; Lkn-1; MIP-1d; HMRP-2B; leukotactin 1; CC chemokine 3; macrophage inflammatory protein 5; chem ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CCL15 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCCL15
Namechemokine (C-C motif) ligand 15
Aliases NCC-3; MIP-5; Lkn-1; MIP-1d; HMRP-2B; leukotactin 1; CC chemokine 3; macrophage inflammatory protein 5; chem ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CCL15 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCCL15
Namechemokine (C-C motif) ligand 15
Aliases NCC-3; MIP-5; Lkn-1; MIP-1d; HMRP-2B; leukotactin 1; CC chemokine 3; macrophage inflammatory protein 5; chem ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CCL15 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2770.369
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1620.787
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.6040.256
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.7030.377
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.7050.667
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6970.735
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2120.471
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolCCL15
Namechemokine (C-C motif) ligand 15
Aliases NCC-3; MIP-5; Lkn-1; MIP-1d; HMRP-2B; leukotactin 1; CC chemokine 3; macrophage inflammatory protein 5; chem ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CCL15. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCCL15
Namechemokine (C-C motif) ligand 15
Aliases NCC-3; MIP-5; Lkn-1; MIP-1d; HMRP-2B; leukotactin 1; CC chemokine 3; macrophage inflammatory protein 5; chem ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CCL15. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CCL15.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCCL15
Namechemokine (C-C motif) ligand 15
Aliases NCC-3; MIP-5; Lkn-1; MIP-1d; HMRP-2B; leukotactin 1; CC chemokine 3; macrophage inflammatory protein 5; chem ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CCL15. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCCL15
Namechemokine (C-C motif) ligand 15
Aliases NCC-3; MIP-5; Lkn-1; MIP-1d; HMRP-2B; leukotactin 1; CC chemokine 3; macrophage inflammatory protein 5; chem ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CCL15 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCCL15
Namechemokine (C-C motif) ligand 15
Aliases NCC-3; MIP-5; Lkn-1; MIP-1d; HMRP-2B; leukotactin 1; CC chemokine 3; macrophage inflammatory protein 5; chem ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CCL15 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCCL15
Namechemokine (C-C motif) ligand 15
Aliases NCC-3; MIP-5; Lkn-1; MIP-1d; HMRP-2B; leukotactin 1; CC chemokine 3; macrophage inflammatory protein 5; chem ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CCL15 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.